Dexamethasone and Kenalog Dosing Guidelines

Chemotherapy-Induced Nausea/Vomiting Management

For high emetic risk chemotherapy, the National Comprehensive Cancer Network recommends 12 mg oral or IV dexamethasone on day 1, followed by 8 mg daily on days 2-4 1, 2
For moderate emetic risk chemotherapy, the American Society of Clinical Oncology suggests 8 mg oral or IV dexamethasone on day 1, followed by 8 mg daily on days 2-3 1, 2
For low emetic risk chemotherapy, the National Comprehensive Cancer Network recommends a single 8 mg oral or IV dose of dexamethasone 1, 2
For breakthrough nausea/vomiting, the National Comprehensive Cancer Network recommends 12 mg oral or IV dexamethasone daily 2

The American College of Rheumatology recommends 40 mg oral or IV dexamethasone daily for immune thrombocytopenic purpura, which is significantly higher than antiemetic dosing 3
For throat pain, a single 10 mg oral or IV dose of dexamethasone is recommended 4
When using dexamethasone with aprepitant for chemotherapy-induced nausea, the dose should be reduced to 12 mg on day 1 and 8 mg on days 2-4 due to drug interaction 1
Oral and IV dexamethasone are equivalent with 1:1 conversion, according to the American Society of Health-System Pharmacists 3, 4, 5

When rescue therapy is needed for breakthrough nausea and vomiting, use a different class of antiemetic than what was given for prophylaxis, as recommended by the World Journal of Emergency Surgery 6
For Postoperative Nausea/Vomiting (PONV), administer a different class of antiemetic than the one used for prophylaxis, with a typical rescue dose of 8 mg if dexamethasone was not used prophylactically, based on the DREAMS trial 6
A dose of 8 mg of dexamethasone showed efficacy in reducing rescue antiemetic needs for up to 72 hours, according to the World Journal of Emergency Surgery 6

The American Heart Association recommends an initial dose of 10 mg IV of dexamethasone in severe exacerbations of asthma in adults, as stated in Circulation 7

The European Society for Medical Oncology suggests that when NK1 antagonists are used concurrently with dexamethasone, doses should be reduced due to drug interactions that increase dexamethasone exposure approximately twofold, as reported in Annals of Oncology 8

The standard anti‑emetic regimen for moderate‑risk chemotherapy recommends 8 mg of dexamethasone per dose【9】.

Both dexamethasone and triamcinolone are glucocorticoids that bind the same steroid receptors, indicating they share the same mechanism of action【9】.

Administration of a single 20 mg dose of dexamethasone can precipitate hyperglycemia, insomnia, and agitation in patients【9】【10】.

The 8 mg dexamethasone dose derived from chemotherapy anti‑emetic guidelines has been inappropriately extrapolated to joint and epidural injection protocols, despite no supporting evidence for such use【9】.
Oncology anti‑emetic protocols have no relevance to joint or epidural steroid injections, underscoring that the dosing rationale is unrelated to musculoskeletal indications【9】.